December 4, 2018
Dear Kinamed Agents and Reps,
The momentum keeps building! We recently shared news of a clinical publication by R. Michael Meneghini, MD on reduced opioid use in tourniquetless TKA patients in which CarboJet played a role (see blog post here). Now Orthopedics Today has picked up the story and is featuring it as the headline story in today’s briefing! See the email below.
This may be just the beginning. The healthcare industry is looking for answers to the opioid epidemic, and this study is providing some. As stated by Dr. Buvanendran’s expert perspective commentary, “Any modality to reduce postoperative pain management in patients undergoing knee replacement should be invigorated.”
And of course, CarboJet is an essential component of Tourniquetless TKA. In fact, Dr. Meneghini has repeatedly stated he wouldn’t feel confident in his cement technique during Tourniquetless TKA without the use of CarboJet.
Be sure to take advantage of this opportunity to be on the winning side of a new standard of care in orthopedics!
Let’s Make it Happen!
Best,
Patrick Miller
Sales & Marketing Manager
Kinamed, Inc.
tel: 1-805-384-2748 x 207
fax: 1-805-384-2792